dc.contributor
Institut Català de la Salut
dc.contributor
[Rico-Fontalvo J] Asociación Colombiana de Nefrología e HTA, Comité de Riñón, Diabetes y Metabolismo, Bogotá, Colombia. Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Departamento de Nefrología, Barranquilla, Colombia. [Reina M] Fundación Universitaria de Ciencias de la Salud, Hospital San José, Departamento de Nefrología, Bogotá, Colombia. [Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Nefrologia i Trasplantament Renal, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud de España (CSUR), Barcelona, Spain. Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), Instituto de Salud Carlos III (RD21/0005/0031), Madrid, Spain. [Unigarro-Palacios M] Fundación Universitaria de Ciencias de la Salud, Hospital San José, Departamento de Endocrinología, Bogotá, Colombia. [Castañeda-González JP] Fundación Universitaria de Ciencias de la Salud, Instituto de Investigaciones, Bogotá, Colombia. [Jiménez Quintero J] Universidad Militar Nueva Granada, Bogotá, Colombia
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Reina, Maricely
dc.contributor.author
Unigarro Palacios, Mario Fernando
dc.contributor.author
Castañeda González, Juan Pablo
dc.contributor.author
Jiménez Quintero, Javier
dc.contributor.author
Rico-Fontalvo, Jorge
dc.contributor.author
Soler, María José
dc.date.accessioned
2025-02-22T17:40:57Z
dc.date.available
2025-02-22T17:40:57Z
dc.date.issued
2025-02-18T09:56:52Z
dc.date.issued
2025-02-18T09:56:52Z
dc.identifier
Rico-Fontalvo J, Reina M, Soler MJ, Unigarro-Palacios M, Castañeda-González JP, Quintero JJ, et al. Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective. Vol. 46, Brazilian Journal of Nephrology. J Bras Nefrol. 2024 Oct-Dec;46(4):e20240101.
dc.identifier
https://hdl.handle.net/11351/12610
dc.identifier
10.1590/2175-8239-JBN-2024-0101en
dc.identifier
001353083500001
dc.identifier.uri
http://hdl.handle.net/11351/12610
dc.description.abstract
Diabetes; Incretins; Kidney disease
dc.description.abstract
Diabetes; Incretinas; Enfermedad renal
dc.description.abstract
Diabetis; Incretins; Malaltia renal
dc.description.abstract
GLP1 receptor agonists (GLP1-RAs) are drugs that mimic the effects of the incretin hormone GLP1 and were initially introduced in medicine for the treatment of diabetes in 2005 and for obesity in 2014. Over time, data from secondary and exploratory objectives of large randomized controlled-trials suggested that GLP1-RAs could also exert renal action by slowing the progression of kidney disease in patients with and without diabetes. Based on this rationale, the Flow study (1 mg semaglutide vs placebo) was designed and recruitment began in 2019 until May 2021. The recently published results confirmed the effect of semaglutide in reducing the composite renal outcome. However, similar to SGLT2 inhibitors, the potential mechanisms behind the renal effects of GLP1-RAs still need to be elucidated. The aim of this review is to address the different physiological mechanisms of GLP1-RAs at the renal level, using evidence from experimental studies and current scientific literature.
dc.format
application/pdf
dc.publisher
Sociedade Brasileira de Nefrologia
dc.relation
Brazilian Journal of Nephrology;46(4)
dc.relation
https://doi.org/10.1590/2175-8239-JBN-2024-0101en
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Diabetis no-insulinodependent - Tractament
dc.subject
Nefropaties diabètiques - Tractament
dc.subject
Antidiabètics - Tractament
dc.subject
Enteroglucagó - Ús terapèutic
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, G-Protein-Coupled::Glucagon-Like Peptide Receptors::Glucagon-Like Peptide-1 Receptor
dc.subject
DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents
dc.subject
DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Nephropathies
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores acoplados a proteínas G::receptores del péptido similar al glucagón::receptor del péptido 1 Similar al glucagón
dc.subject
ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::hipoglicemiantes
dc.subject
ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::nefropatías diabéticas
dc.title
Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective
dc.title
Efeitos renais do Peptídeo 1 Semelhante ao Glucagon (GLP1): das bases moleculares a uma perspectiva farmacofisiológica
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
